# A 28 Day Parallel Group Study to Assess the Effects of RDN-929

> **NCT03963973** · PHASE1 · TERMINATED · sponsor: **Alkermes, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** RDN-929 oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03963973
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-16
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-22
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Participants no longer receiving intervention
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963973, "A 28 Day Parallel Group Study to Assess the Effects of RDN-929". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03963973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*